This is a Phase 2, multicenter, single-arm, monotherapy study of zanubrutinib in approximately 60 patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were intolerant to prior ibrutinib treatment as defined per protocol. Patients must have achieved a response to prior ibrutinib therapy of at least SD at enrollment. Patients who have received intervening anticancer therapy between ibrutinib and zanubrutinib are excluded. The primary endpoint is safety of zanubrutinib as measured by the frequency and severity of selected events (ie, diarrhea; myalgia/arthralgia; hypertension; fatigue; muscle spasms; rash; atrial fibrillation and hemorrhage, excluding central nervous system bleeding).
21st Century Oncology will be moving to their new home as part of the global GenesisCare network. The 21st Century Oncology website will no longer exist after November 2020.
There will be no disruption in your care team, location, or contacts. There will simply be a new website, new look and feel, and patients will benefit from the latest treatment technology and evidence-based cancer care. We look forward to serving you as part of the GenesisCare team.